Microbot Medical MBOT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Microbot Medical in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Microbot Medical's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Microbot Medical's cash & equivalents?
- Microbot Medical (MBOT) reported cash & equivalents of $3.66M in Q1 2026.
- How has Microbot Medical's cash & equivalents changed year-over-year?
- Microbot Medical's cash & equivalents increased by 13.7% year-over-year, from $3.22M to $3.66M.
- What is the long-term trend for Microbot Medical's cash & equivalents?
- Over 5 years (2020 to 2025), Microbot Medical's cash & equivalents has grown at a -27.6% compound annual growth rate (CAGR), from $19.65M to $3.91M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.